Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock*

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Critical Care Medicine

• Publication date

  2007-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.CCM.0000266755.75844.05PMID 17452932
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia

  2006cited by this paper
• The ubiquitin proteolytic system: from an idea to the patient bed.

  2006cited by this paper
• Optimal therapy for severe pneumococcal community-acquired pneumonia

  2006cited by this paper
• The impact of prior outpatient ACE inhibitor use on 30-day mortality for patients hospitalized with community-acquired pneumonia

  2005cited by this paper
• The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia.

  2005cited by this paper
• Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival.

  2005cited by this paper
• Monotherapy versus combination antimicrobial therapy for pneumococcal pneumonia

  2005influential reference
• Worldwide perspective of the quality of care provided to hospitalized patients with community-acquired pneumonia: results from the CAPO international cohort study.

  2005cited by this paper
• Medium-term survival after hospitalization with community-acquired pneumonia.

  2004cited by this paper
• Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia.

  2004cited by this paper
• Surviving pneumonia--just a short-term lease on life?

  2004cited by this paper
• Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients.

  2004cited by this paper
• Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia.

  2003cited by this paper
• Update of Practice Guidelines for the Management of Community-Acquired Pneumonia in Immunocompetent Adults

  2003cited by this paper
• Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability.

  2002cited by this paper
• Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria.

  2002cited by this paper
• Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States.

  2002cited by this paper
• Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia.

  2001influential reference
• Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial.

  2000cited by this paper
• Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978-1997.

  1999cited by this paper
• Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis.

  1996cited by this paper

• Management of community-acquired pneumonia in immunocompetent adults: updated Swedish guidelines

  2025cites this paper
• Questioning the Addition of Fluoroquinolone on Mortality in Severe Community-Acquired Pneumonia: A multicenter study in Korea.

  2025cites this paper
• Developing and validating a prognostic model to predict ICU mortality in patients with sepsis-associated thrombocytopenia: a retrospective cohort study based on MIMIC-IV

  2025cites this paper
• Pneumonies communautaires graves de l’adulte immunocompétent, hors Covid-19

  2023cites this paper
• Polmoniti gravi acquisite in comunità in adulti immunocompetenti, escluso Covid-19

  2023cites this paper
• Neumonías comunitarias graves del adulto inmunocompetente, excepto COVID-19

  2023cites this paper
• Association between Glucocorticoids and Mortality in Patients with Severe Pneumonia: A Systematic Review and Meta-Analysis Based on Randomized Controlled Trials

  2022cites this paper
• Older Adults Hospitalized for Pneumonia in the United States: Incidence, Epidemiology, and Outcomes

  2020cites this paper
• Usefulness of β-lactam and macrolide combination therapy for treating community-acquired pneumonia patients hospitalized in the intensive care unit: Propensity score analysis of a prospective cohort study.

  2020cites this paper
• Updates on community acquired pneumonia management in the ICU

  2020cites this paper
• Community-acquired bacterial pneumonia in adults: An update

  2020cites this paper
• S3-Leitlinie Sepsis – Prävention, Diagnose, Therapie und Nachsorge

  2020cites this paper
• Efficacy of clarithromycin against H5N1 and H7N9 avian influenza a virus infection in cynomolgus monkeys.

  2019cites this paper
• Considerations for the Use of Polyphenols as Therapies in Neurodegenerative Diseases

  2019cites this paper
• Beta-lactam plus a Macrolide versus a Fluoroquinolone for Empiric Therapy of Hospitalized Patients with Community-Acquired Pneumonia: Results from the University of Louisville Pneumonia Study

  2019cites this paper
• Антибактериальная терапия тяжёлой внебольничной пневмонии у взрослых - нужны ли новые препараты?

  2019cites this paper
• Mortality in patients with community‐onset pneumonia at low risk of drug‐resistant pathogens: Impact of β‐lactam plus macrolide combination therapy

  2018cites this paper
• Sepsis and Septic Shock

  2018cites this paper
• Effectiveness of combination therapy versus monotherapy with a third-generation cephalosporin in bacteraemic pneumococcal pneumonia: A propensity score analysis.

  2018cites this paper
• Community-acquired Pneumonia

  2018cites this paper
• Tigecycline salvage therapy for critically ill children with multidrug-resistant/extensively drug-resistant infections after surgery.

  2018cites this paper
• Severe community-acquired pneumonia: current management and future therapeutic alternatives

  2018cites this paper
• Guidelines to Manage Community-Acquired Pneumonia.

  2018cites this paper
• Impact of antibiotic therapy in severe community‐acquired pneumonia: Data from the Infauci study

  2018cites this paper
• Pneumonia, Community-Acquired

  2017cites this paper
• Investigational drugs in phase I and phase II clinical trials for the treatment of community-acquired pneumonia

  2017cites this paper
• Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016

  2017cites this paper
• Macrolide therapy for patients with pneumonia: a triple-edged sword

  2017cites this paper
• Moxifloxacin monotherapy versus combination therapy in patients with severe community-acquired pneumonia evoked ARDS

  2017cites this paper
• Precision medicine for the treatment of severe pneumonia in intensive care

  2016cites this paper
• Association of macrolides with overall mortality and cardiac death among patients with various infections: A meta-analysis.

  2016cites this paper
• Study of a prescribing pattern of empirical antibiotics in patients with sepsis in a tertiary care hospital of Eastern India

  2016cites this paper
• Pharmacodynamic Issues in Antibiotic Combinations

  2016cites this paper
• Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia?

  2016cites this paper
• Host-directed therapies for infectious diseases: current status, recent progress, and future prospects

  2016cites this paper
• Predictive and prognostic factors in patients with blood-culture-positive community-acquired pneumococcal pneumonia

  2016cites this paper
• Efficacy and Safety of Adjunctive Corticosteroids Therapy for Severe Community-Acquired Pneumonia in Adults: An Updated Systematic Review and Meta-Analysis

  2016cites this paper
• The prognostic value of muscle regional oxygen saturation index in severe community-acquired pneumonia: a prospective observational study

  2016cites this paper
• Is β-Lactam Plus Macrolide More Effective than β-Lactam Plus Fluoroquinolone among Patients with Severe Community-Acquired Pneumonia?: a Systemic Review and Meta-Analysis

  2016cites this paper
• Past, present and future of macrolide therapy for chronic rhinosinusitis in Japan.

  2016cites this paper
• The solithromycin journey-It is all in the chemistry.

  2016cites this paper
• id-regional proadrenomedullin : An early marker of esponse in critically ill patients with severe ommunity-acquired pneumonia ?

  2016cites this paper
• Macrolides and respiratory infection in critically ill patients: what is the next step?

  2016cites this paper
• Intensivtherapie bei Pneumonien

  2015cites this paper
• Optimizing Antimicrobial Therapy of Sepsis and Septic Shock: Focus on Antibiotic Combination Therapy

  2015cites this paper
• Polmoniti comunitarie gravi dell’adulto immunocompetente

  2015cites this paper
• Neumonías comunitarias graves del adulto inmunocompetente

  2015cites this paper
• What Is New in Antibiotic Therapy in Community-Acquired Pneumonia? An Evidence-Based Approach Focusing on Combined Therapy

  2015cites this paper
• Neumonía adquirida en la comunidad

  2015cites this paper
• Managing CAP in the ICU

  2015cites this paper
• Causes of non-adherence to therapeutic guidelines in severe community-acquired pneumonia

  2015cites this paper
• Update on the combination effect of macrolide antibiotics in community-acquired pneumonia.

  2015cites this paper
• The bacterial pneumonias: a new treatment paradigm

  2015cites this paper
• Improving outcomes from community-acquired pneumonia

  2015cites this paper
• Pneumonies communautaires graves de l’adulte immunocompétent

  2015cites this paper
• Synergy effects of herb extracts: pharmacokinetics and pharmacodynamic basis.

  2014cites this paper
• Look at your patient: appropriate antimicrobial therapy in patients with community- versus hospital-acquired bacteremic sepsis

  2014cites this paper
• Oxidative stress in immunocompetent patients with severe community-acquired pneumonia. A pilot study.

  2014cites this paper
• „Tarragona-Strategie“

  2014cites this paper
• Cardiovascular events and safety outcomes associated with azithromycin therapy: a meta-analysis of randomized controlled trials.

  2014cites this paper
• Pneumonia in immunocompetent patients: combination antibiotic therapy.

  2014cites this paper
• Determining need for hospitalisation: Evaluation of the utility of the CRB-65 score in patients with community-acquired pneumonia presenting to an emergency department.

  2014cites this paper
• Acute Pneumonia

  2014cites this paper
• β-Lactam/macrolide dual therapy versus β-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis.

  2014cites this paper
• Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia.

  2014cites this paper
• [Tarragona strategy--appropriate antibiotic therapy in the ICU].

  2014cites this paper
• β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.

  2014cites this paper
• Impact of macrolide therapy in patients hospitalized with Pseudomonas aeruginosa community-acquired pneumonia.

  2014cites this paper
• Management of severe community-acquired pneumonia: a survey on the attitudes of 468 physicians in Iberia and South America.

  2014cites this paper
• Macrolides and Mortality in Critically Ill Patients With Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis*

  2014cites this paper
• „Tarragona-Strategie“ – adäquate Antibiotikatherapie auf der Intensivstation

  2014cites this paper
• The management of severe community acquired pneumonia in the intensive care unit

  2014cites this paper
• Corticosteroid Therapy for Severe Community-Acquired Pneumonia: A Meta-Analysis

  2014influential citation
• b-Lactam / macrolide dual therapy versus b-lactam monotherapy for the treatment of community-acquired pneumonia in adults : a systematic review and meta-analysis

  2014cites this paper
• Severe community‐acquired pneumonia treated with β‐lactam–respiratory quinolone vs. β‐lactam–macrolide combination

  2013cites this paper
• An alternate pathophysiologic paradigm of sepsis and septic shock

  2013cites this paper
• Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies

  2013cites this paper
• Current treatment of community-acquired pneumonia

  2013cites this paper
• Does empiric therapy for atypical pathogens improve outcomes for patients with CAP?

  2013cites this paper
• Community-acquired Legionella Pneumonia in the intensive care unit: Impact on survival of combined antibiotic therapy.

  2013cites this paper
• Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia

  2013cites this paper
• Can we predict pneumococcal bacteremia in patients with severe community-acquired pneumonia?

  2013cites this paper
• What is the best antimicrobial treatment for severe community-acquired pneumonia (including the role of steroids and statins and other immunomodulatory agents).

  2013cites this paper
• Bacteriological Profile and Antibiotic Sensitivity Pattern of Micro Organisms from Community Acquired Pneumonia.

  2013cites this paper
• Long-term prognosis in community-acquired pneumonia

  2013cites this paper
• Severe Community-Acquired Pneumonia

  2013influential citation
• Bronchopulmonale Infektionen

  2013cites this paper
• Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance

  2013cites this paper
• Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012

  2013cites this paper
• Macrolide use in the treatment of critically ill patients with pneumonia: Incidence, correlates, timing and outcomes.

  2013influential citation
• Community-acquired pneumonia: identification and evaluation of nonresponders

  2013influential citation
• Evaluation of the IDSA/ATS Minor Criteria for Severe Community-Acquired Pneumonia

  2012cites this paper
• First influenza season after the 2009 pandemic influenza: characteristics of intensive care unit admissions in adults and children in Vall d'Hebron Hospital.

  2012cites this paper
• Antibiotic treatment for severe community-acquired pneumonia: beyond antimicrobial susceptibility.

  2012cites this paper
• Adjunctive Therapy in Community-Acquired

  2012cites this paper
• The use of the CRB-65 severity of illness score to determine the need for admission of patients with community-acquired pneumonia presenting to an emergency department

  2012cites this paper
• Treatment of Sepsis-Related Organ Dysfunction—Reply

  2012cites this paper
• Место внутривенной формы азитромицина в лечении внебольничной пневмонии

  2012cites this paper
• Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study

  2012cites this paper
• Predicting ICU admission in community-acquired pneumonia: clinical scores and biomarkers

  2012cites this paper